| Best of ASCO 2024 | Mumbai | Taj Mahal Palace | |||
|---|---|---|---|
| Day 1 - Friday, 04 October 2024 | |||
| Main Hall - (TBD) (TBD) |
|||
| Time in Hrs (IST) | Track Code | Topic | Role |
| Session 01 | Track: Health Economics | |||
| Chairpersons: TBD | Presenters | ||
| 16:00 - 17:00 | TBD (60 mins) |
Breast cancer in the region update and challenges and followed by press meet | TBD (Presenter) |
| Moderator : TBD | Panelists | ||
| 17:00 - 18:00 | TBD (20 mins) |
Financing healthcare including health policy | TBD (Presenter) |
| TBD (20 mins) |
Economics evaluation of health technologies | TBD (Presenter) |
|
| TBD (20 mins) |
Big data in healthcare | TBD (Presenter) |
|
| Followed by dinner | |||
| Day 2 - Saturday, 05 October 2024 | |||
|---|---|---|---|
| Main Hall - (TBD) (TBD) |
|||
| Session 02 | Tracks: (i) Breast Cancer—Local/Regional/Adjuvant | |||
| Chairperson: (TBD) | Presenters | ||
| 08:30 - 09:00 | TBD (07 mins) |
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. | TBD (Presenter) |
| TBD (07 mins) |
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. | TBD (Presenter) |
|
| TBD (07 mins) |
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). | TBD (Presenter) |
|
| TBD (07 mins) |
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). | TBD (Presenter) |
|
| Moderators: (TBD) | Panelists | ||
| 09:00 - 09:30 | PD (30 mins) |
Panel Discussion on Track: (i) Breast Cancer—Local/Regional/Adjuvant | TBD (Presenter) |
| Chairperson: (TBD) | Speakers / Panelists | ||
| 09:30 - 10:00 | IS (15 * 2 mins) |
Industry Talk | TBD (Presenter) |
| Session 03 | Tracks: (ii) Breast Cancer—Metastatic | |||
| Chairperson: TBD | Presenters | ||
| 10:00 - 10:30 | TBD (07 mins) |
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). | TBD (Presenter) |
| TBD (07 mins) |
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. | TBD (Presenter) |
|
| TBD (07 mins) |
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD). | TBD (Presenter) |
|
| GC-GPH (7 mins) |
TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. | TBD (Presenter) |
|
| Moderators: (TBD) | Panelists | ||
| 10:30 - 11:00 | PD (30 mins) |
Panel Discussion on Track: (ii) Breast Cancer—Metastatic | TBD (Panelists) |
| Chairperson: TBD | Speakers / Panelists | ||
| 11:00 - 11:30 | IS (15 * 2 mins) |
Industry Talk | TBD(Panelists) TBD(Speakers) |
| 11:30 - 11:45 | (15 mins) | Tea Break | |
| Session 04 | Tracks: (i) Head and Neck Cancer | |||
| Chairperson: TBD | Presenters | ||
| 11:45 - 12:15 | TBD (07 mins) |
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial. | TBD (Presenter) |
| TBD (07 mins) |
Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC). | TBD (Presenter) |
|
| TBD (07 mins) |
A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study. | TBD (Presenter) |
|
| TBD (07 mins) |
TBD | TBD (Presenter) |
|
| Moderators: (TBD) | Panelists | ||
| 12:15 - 12:45 | PD (30 mins) |
Panel Discussion on Track: (i) Head and Neck Cancer | TBD (Panelists) |
| Chairperson: TBD | Speakers / Panelists | ||
| 12:45 - 13:15 | IS (15 * 2 mins) |
Industry Talk | TBD(Panelists) TBD(Speakers) |
| 13:15 - 14:00 | (45 mins) | Lunch | |
| 14:00 - 14:45 | (45 mins) | Plenary Talk - TBD | Dr. B.S. Ajaikumar (RO & MO) Executive Chairman, HCG Hospitals |
| Session 05 | Tracks: (i) Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | |||
| Chairperson: TBD | Presenters | ||
| 14:45 - 15:15 | TBD (07 mins) |
DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis. | TBD (Presenter) |
| TBD (07 mins) |
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial. | TBD (Presenter) |
|
| TBD (07 mins) |
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. | TBD (Presenter) |
|
| TBD (07 mins) |
ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). | TBD (Presenter) |
|
| Moderators: (TBD) | Panelists | ||
| 15:15 - 15:45 | PD (30 mins) |
Panel Discussion on Track: (i) Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | TBD (Panelists) |
| Chairperson: TBD | Speakers / Panelists | ||
| 15:45 - 16:15 | IS (15 * 2 mins) |
Industry Talk | TBD(Panelists) TBD(Speakers) |
| 16:15 - 16:30 | (15 mins) | Tea Break | |
| Session 06 | Tracks: (ii) Lung Cancer—Non-Small Cell Metastatic | |||
| Chairperson: TBD | Presenters | ||
| 16:30 - 17:00 | TBD (07 mins) |
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. | TBD (Presenter) |
| TBD (07 mins) |
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. | TBD (Presenter) |
|
| TBD (07 mins) |
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. | TBD (Presenter) |
|
| TBD (07 mins) |
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). | TBD (Presenter) |
|
| Moderators: (TBD) | Panelists | ||
| 17:00 - 17:30 | PD (30 mins) |
Panel Discussion on Track: (ii) Lung Cancer—Non-Small Cell Metastatic | TBD (Panelists) |
| Chairperson: TBD | Speakers / Panelists | ||
| 17:30 - 18:00 | IS (15 * 2 mins) |
Industry Talk | TBD(Panelists) TBD(Speakers) |
| 18:00 - 18:30 | (30 mins) | Break | |
| 18:30 - 20:30 | (30 mins) | Dinner Symposium Topic: TBD Followed by Gala Dinner |
TBD |
| Day 3 - Sunday, 6 October 2024 | |||
|---|---|---|---|
| TBD (TBD) |
|||
| Session 07 || Track: (i) Hematologic Malignancies—Plasma Cell Dyscrasia | |||
| Chairperson: TBD | Presenters | ||
| 09:00 - 09:30 | TBD (07 mins) |
All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D. | TBD (Presenter) |
| TBD (07 mins) |
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). | TBD (Presenter) |
|
| TBD (07 mins) |
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). | TBD (Presenter) |
|
| TBD (07 mins) |
TBD | TBD (Presenter) |
|
| Moderators: (TBD) | Panelists | ||
| 09:30 - 10:00 | PD (30 mins) |
Panel Discussion on Track: (i) Hematologic Malignancies—Plasma Cell Dyscrasia | TBD (Panelists) |
| Chairperson: TBD | Speakers / Panelists | ||
| 10:00 - 10:30 | IS (15 * 2 mins) |
Industry Talk | TBD(Panelists) TBD(Speakers) |
| Session 08 || Track: FGT 1 - Female Genitourinary Tract | |||
| Chairperson: TBD | Presenters | ||
| 10:30 - 11:00 | TBD (07 mins) |
Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724. | TBD (Presenter) |
| TBD (07 mins) |
TBD | TBD (Presenter) |
|
| TBD (07 mins) |
TBD | TBD (Presenter) |
|
| TBD (07 mins) |
TBD | TBD (Presenter) |
|
| Moderators: (TBD) | Panelists | ||
| 11:00 - 11:30 | PD (30 mins) |
Panel Discussion on Track: FGT 1 - Female Genitourinary Tract | TBD (Panelists) |
| Chairperson: TBD | Speakers / Panelists | ||
| 11:30 - 12:00 | IS (15 * 2 mins) |
Industry Talk | TBD(Panelists) TBD(Speakers) |
| 12:00 - 12:45 | (45 mins) | Keynote Speaker | TBD |
| 12:45 - 13:30 | (45 mins) | Lunch | |
| Session 09 || Track: (i) Gastrointestinal Cancer - Colorectal and Anal | |||
| Chairperson: TBD | Presenters | ||
| 13:30 - 14:00 | TBD (07 mins) |
Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial. | TBD (Presenter) |
| TBD (07 mins) |
Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET). | TBD (Presenter) |
|
| TBD (07 mins) |
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW. | TBD (Presenter) |
|
| TBD (07 mins) |
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial. | TBD (Presenter) |
|
| Moderators: (TBD) | Panelists | ||
| 14:00 - 14:30 | PD (30 mins) |
Panel Discussion on Track: (i) Gastrointestinal Cancer - Colorectal and Anal | TBD (Panelists) |
| Chairperson: TBD | Speakers / Panelists | ||
| 14:30 - 15:00 | IS (15 * 2 mins) |
Industry Talk | TBD(Panelists) TBD(Speakers) |
| Session 10 || Track: GU 1 - Genitourinary Tract | |||
| Chairperson: TBD | Presenters | ||
| 15:00 - 15:30 | TBD (07 mins) |
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. | TBD (Presenter) |
| TBD (07 mins) |
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). | TBD (Presenter) |
|
| TBD (07 mins) |
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. | TBD (Presenter) |
|
| TBD (07 mins) |
TBD | TBD (Presenter) |
|
| Moderators: (TBD) | Panelists | ||
| 15:30 - 16:00 | PD (30 mins) |
Panel Discussion on Track: GU 1 - Genitourinary Tract | TBD (Panelists) |
| Chairperson: TBD | Speakers / Panelists | ||
| 16:00 - 16:30 | IS (15 * 2 mins) |
Industry Talk | TBD(Panelists) TBD(Speakers) |
| 16:30 - 16:45 | IS (15 mins) |
Working Tea & Closing | |
Copyright© 2023 Designed & Developed by GHA Conferences